Anti-GD2 chimeric antigen receptor T-cell therapy (University College London)

N/A

Report date: 2022/09/19 10:05:59

Base Information

Drug NameAnti-GD2 chimeric antigen receptor T-cell therapy (University College London)
Drug Alias NameGD2 CAR T cells (University College London)T-cell replacement therapy- Autolus (University College London)AUTO6
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-GD2
TargetsDisialoganglioside GD2
Therapy Area/IndicationsDiffuse midline gliomaNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesAutolusUniversity College London
Inactive CompaniesN/A
Active IndicationsDiffuse midline gliomaNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A